investor harm

Enphase Energy faces class action lawsuit for allegedly misleading investors about inventory management and tax credit expiration impact during April-October 2025.

uniQure faces class action lawsuit alleging misleading statements about FDA study status and BLA timeline delays. Investors who purchased shares Sept-Oct 2025 may be eligible to claim.

PomDoctor faces class action lawsuit alleging fraudulent stock promotion scheme involving false statements, insider sales, and market manipulation between October-December 2025.

REGENXBIO faces class action lawsuit alleging executives made false statements about RGX-111 gene therapy's efficacy and safety, seeking shareholder damages.

Class action lawsuit filed against Picard Medical for alleged securities fraud involving false statements, insider share sales, and social media misinformation to artificially inflate stock price.

Oracle faces a class action lawsuit alleging it failed to disclose financial risks tied to its AI infrastructure investments, citing misaligned capital spending and revenue growth.

Mereo BioPharma faces class action lawsuit over allegedly false statements regarding failed Phase 3 clinical trials. Investors who bought securities between June 2023-December 2025 may be eligible to participate.

Class action lawsuit filed against Klarna over IPO disclosure claims, alleging risk reserves were materially understated in regulatory filings.

Varonis Systems faces class action lawsuit alleging false statements about SaaS conversion capabilities inflated stock prices. Investors who bought shares between February-October 2025 may qualify.

Class action lawsuit filed against NuScale Power for allegedly misrepresenting nuclear partner ENTRA1's experience. Investors claim material misstatements about partner's qualifications were not disclosed timely.

Class action lawsuit filed against agilon health for allegedly making false 2026 guidance claims and overstating financial benefits of risk-reduction initiatives, harming investors.

Ramaco Resources faces class action lawsuit for allegedly misleading investors about Brook Mine operations. Executives reportedly made false statements about the facility's status despite holding a public groundbreaking ceremony.

Masonite faces class action lawsuit alleging executives concealed acquisition offers while repurchasing stock at depressed prices. Investors who bought shares June 2023-February 2024 are eligible.

Class action lawsuit filed against CoreWeave for allegedly making false statements about operational capabilities and customer demand fulfillment. Investors who purchased stock during specified period may seek lead plaintiff status.

Beyond Meat faces class action lawsuit alleging leadership concealed material asset impairment charges, misleading investors during nine-month period ending November 2025.

REGENXBIO faces securities class action alleging false statements about RGX-111 gene therapy program and clinical trial outcomes. Investors from February 2022-January 2026 may recover damages.

uniQure faces class action lawsuit alleging misleading FDA approval statements and understated BLA timeline risks. Investors who purchased securities between September-October 2025 may be eligible to participate.

BlackRock TCP Capital faces class action lawsuit alleging false valuations and misleading net asset value disclosures. Shareholders who bought shares between November 2024 and January 2026 may participate.

Paysafe Limited faces class action lawsuit alleging undisclosed risks including high-risk client concentration and understated credit reserves, misleading investors about financial stability.

CIBC and RBC face class action lawsuit for allegedly using spoofed orders to manipulate Quantum Biopharma stock price downward, harming investors from 2021-2025.